



30 October 2026

CONNEQT HEALTH SEPTEMBER 2026 QUARTER UPDATE

Highlights:

- **Group revenue of \$1.18 million**, up 86% on the September 2025 quarter (\$0.63 million) and down 48% on the June 2026 quarter (\$2.28 million), primarily reflecting the temporary interruption in Pulse inventory availability.
- **Research and pharmaceutical business revenue of \$0.70 million** (June quarter: \$0.85 million), including \$0.26 million from pharmaceutical clinical trial services.
- **Enterprise business** continued developing its recurring clinical subscription model. Contracted clinical sites increased to 20, with ARR increasing to \$103.2K.
- **Consumer revenue of \$0.45 million**, following a temporary interruption in Pulse inventory availability from July through mid-August.
- **New partnerships**, including longevity influencer Bryan Johnson's online Blueprint Marketplace store, to drive consumer adoption.
- **Paid customer acquisition expenditure reduced 38%** due to inventory restrictions, the reassessment of paid advertising economics, and the shift to a more disciplined, contribution-focused growth model.
- **New device bundles incorporating Care+ and accessories demonstrated continued early traction**, representing 13% of device orders, with an average order value increasing to US\$384.
- **Digital revenue represented 11% of consumer revenue**, up from 3% last quarter, with monthly Care+ billings remaining stable despite lower device sales.
- **Consumer business model under review**, including a more accessible Pulse entry price with advanced cardiovascular features available through Care+, intended to expand adoption and recurring revenue.
- **Pulse v2 development continues toward launch in early 2027**, with product, engineering, and supply chain initiatives targeting manufacturing cost reductions exceeding 50% (~US\$50) per device.
- **SphygmoCloud FDA Pre-Submission**: Positive FDA feedback received, with commercial launch targeted alongside Pulse v2 in early 2027.
- **Balance sheet strengthened** through the conversion of \$1.275 million of related party loans to equity, together with \$1.10 million of cash proceeds from the Share Purchase Plan and Tranche 2 of the June 2026 Placement.
- **Closing cash of \$0.50 million** as at 30 September 2026. The Board is progressing a funding package comprising both debt and equity, including receipt of the FY2026 R&D Tax Incentive refund (approximately \$1.5 million) expected in the December 2026 quarter.

C O N N E Q T.
Health

CONNEQT Health, LTD.
ASX: CQT

Info@conneqthealth.com
conneqthealth.com

Suite 301, 55 Lime St
Sydney NSW 2000
Australia

+61 2 9874 8761



Enterprise

Expanding the Recurring Clinical Subscription Business

CONNEQT continued developing its enterprise business during the September quarter, building on the subscription-based commercial model introduced in January 2026.

The enterprise strategy focuses on enabling healthcare providers to incorporate advanced cardiovascular assessment into routine clinical workflows through a combination of connected measurement devices, software and ongoing service relationships.

The subscription model is designed to reduce the upfront capital expenditure required by clinical customers while creating recurring revenue opportunities for CONNEQT. This approach provides an opportunity to establish longer-term clinical relationships while extending the commercial application of its established cardiovascular measurement technologies.

During the quarter, the Company signed 4 new enterprise subscription agreements, bringing the total number of contracted clinical sites to 20 (net of one cancellation). Clinical subscription annual recurring revenue reached \$103.2K, up from \$94.2K at 30 June 2026, and cumulative contracted value reached \$184.0K, up from \$163.8K at 30 June 2026.

Enterprise revenue recognised for the quarter was \$33.7K, comprising subscription fees of \$19.5K and implementation fees of \$14.2K.

Management remains focused on increasing the number of clinical sites, improving utilisation within the installed base and building recurring assessment revenue. The near-term focus remains on converting contracted sites into active clinical users, expanding subscription adoption and improving the contribution generated from the enterprise installed base.

Supporting Scientific Leadership, Research, and Commercial Diversification

The Company's research and pharmaceutical business continued supporting cardiovascular research through its industry gold standard SphygmoCor product portfolio. SphygmoCor technology has an extensive history of use in pharmaceutical trials, academic research and clinical investigations, providing a differentiated scientific foundation for the broader CONNEQT platform.

Research revenue for the September quarter was **\$0.70 million**, compared with **\$0.85 million** in the preceding quarter. Revenue comprised pharmaceutical clinical trial services of \$0.26 million, U.S. academic research of \$0.32 million, U.S. clinical sales of \$0.05 million and international distributor sales of \$0.07



million. Compared with the September 2025 quarter (\$0.26 million), research revenue increased 174%, reflecting a stronger performance in all regions, as well as the contribution of the U.S. Phase 2b pharmaceutical clinical trial. **At quarter end research receivables were approximately \$0.8 million, which are expected to be received in the December 2026 quarter.**

Management views the research business as an important source of commercial diversification and scientific credibility. Its established relationships with researchers, pharmaceutical companies and clinical investigators also provide opportunities to support the validation and development of future SphygmoCor cardiovascular biomarkers.

Consumer

Consumer Performance and Operational Reset

Consumer revenue for the September quarter was \$0.45 million, compared with \$1.39 million in the prior quarter, comprising Pulse device and accessory sales of \$0.40 million and digital revenue of \$0.05 million.

Pulse unit sales for the quarter were 1,015 devices, compared with 3,574 in the prior quarter.

Following four consecutive quarters of strong growth, the September quarter performance was affected by a two-month interruption in product availability and a consequent decision to reduce paid customer acquisition expenditure.

The Company entered the quarter with positive growth trends across key performance metrics. However, capital constraints limited our ability to maintain adequate inventory, disrupting product availability and requiring us to scale back marketing spend and sales activity. These factors directly impacted revenue for the quarter.

As highlighted in the CEO's shareholder video message last month, scaling our installed device base requires substantial upfront investment in inventory, marketing, customer acquisition, fulfilment, and customer support. That investment enables us to place devices with more customers, whose full lifetime value (LTV) is realised over time through the initial device sale and ongoing Care+ subscription revenue. This means we must commit capital upfront to grow our installed device base, while the full lifetime value of each customer is realised over time.

The weaker quarterly performance reflects capital and inventory constraints that interrupted that growth trajectory - not a lack of underlying momentum or demand.



Following the restoration of inventory availability in August, the Company increased device pricing and introduced new device bundles incorporating Care+ subscriptions and accessories.

Average device order value increased 10% to US\$290 and hardware gross margin improved to 59% (from 55%).

The new bundles demonstrated encouraging early adoption, representing 13% of device orders following the restock, or 10.5% across the quarter, with an average order value of US\$384.

These results continued to provide evidence of the opportunity to increase transaction value through integrated hardware and digital offerings.

The Company subsequently resumed paid customer acquisition activities to restore demand. However, customer acquisition costs during the restart were higher than anticipated, reflecting increased advertising costs and competition across paid digital platforms, together with lower initial conversion rates as campaigns were re-established.

As a result, management reduced paid acquisition expenditure from mid-September, with total expenditure for the quarter reducing to US\$0.49 million, a reduction of 38% compared with the preceding quarter.

Transitioning to an Efficiency-Led Growth Model

The September quarter reinforced findings from analysis undertaken during June, which indicated that paid customer acquisition becomes increasingly challenging at higher expenditure levels, with diminishing returns as marketing expenditure scales.

Several pressures drove the cost increase:

- **Higher media prices.** Meta reported a 12% year-on-year rise in average price per ad in its June quarter results, its second consecutive quarterly increase. On our own account, Meta's cost per thousand impressions rose about 60% against H1 at comparable spend.
- **Health category costs.** Industry benchmarks show health and fitness search costs up about 23% year-on-year, and advertising rules for health and wellness products are being more strictly enforced by regulators.
- **Seasonal and political competition.** US midterm election spending and the holiday period are expected to keep advertising prices high through the December quarter.

The increase in paid customer acquisition costs has prompted management to optimise pricing to make the device more accessible and reposition our marketing strategy to be weighted more around organic, social, email, influencer, content marketing, and earned media. The objective is to improve conversion



rates and customer acquisition efficiency while increasing the proportion of lifetime customer value generated through recurring digital services.

Management is also prioritising improvements in website conversion and increasing the proportion of device purchases incorporating Care+ subscriptions and accessories.

While this approach may result in lower near-term device sales volumes, the objective is to improve contribution per customer and establish a more sustainable foundation for consumer growth and recurring revenues through Care+ purchases.

The Company believes that improvements in customer acquisition efficiency, combined with increasing recurring digital revenue, will become increasingly important drivers of the consumer business's long-term economics.

Evolving the Consumer Business Model

Building on the early adoption of Care+ bundles, CONNEQT is evaluating a further evolution of its consumer commercial model designed to accelerate device adoption and increase recurring digital revenue.

As an immediate initiative, ahead of the planned introduction of Pulse v2 in early 2027, the Company is evaluating a reduction in the entry price of the existing CONNEQT Pulse, with advanced cardiovascular measurement features and insights only available through a Care+ subscription through the app.

This approach has the potential to reduce the upfront cost barrier to adoption, expand the addressable consumer market and establish a clearer value proposition for subscription services.

Importantly, the proposed model can be introduced using existing Pulse hardware, allowing the Company to begin transitioning its commercial model ahead of the next-generation Pulse v2 device in early 2027.

The initiative builds on early commercial evidence from the Company's existing Care+ bundles, which have demonstrated consumer willingness to purchase integrated hardware and subscription offerings.

The proposed pricing and subscription structure will be evaluated against customer acquisition costs, subscription attachment, retention and lifetime customer contribution to ensure that increased adoption translates into sustainable economics.

Our business model is increasingly focused on monetising software services and recurring subscription revenues, initially through Care+ subscriptions associated with the Pulse device, and expanding further with the introduction of Pulse v2.



Pulse v2 and Structural Cost Improvements

The Company continues progressing the development of Pulse v2, targeting introduction in early-2027. Pulse v2 is being developed to become the first arterial health monitor supported by an FDA-cleared cloud-based software platform, enabling the processing and analysis of our proprietary cardiovascular biomarkers to shift from device hardware to the cloud. This transition represents a significant evolution in our technology architecture, enabling significant reductions in hardware costs, greater scalability, accelerated software-driven innovation, and expanded opportunities for recurring subscription revenue.

The next-generation device is being designed around a more cost-efficient hardware architecture, with product, engineering and supply chain initiatives targeting aggregate cost reductions exceeding 50% (~US\$50) per device.

The introduction of Pulse v2 is expected to further improve hardware contribution margins through a structurally lower manufacturing cost base. Importantly, by shifting biomarker processing to the cloud and delivering results through the CONNEQT app, Pulse v2 is intended to be marketed as an over-the-counter (OTC) product **without the need for a prescription (which is currently required for the existing Pulse)**, subject to applicable regulatory requirements. This would significantly expand the Company's distribution opportunities, including Amazon and other direct-to-consumer channels.

The underlying strategy is to drive broad market adoption by making Pulse v2 available at an affordable price, maximising the number of devices in consumers' hands, and monetising that growing installed base primarily through recurring app subscriptions that provide access to our proprietary cardiovascular biomarkers and associated health insights. This approach is designed to establish a scalable, software-led recurring revenue model, with hardware serving as the primary driver of customer acquisition and long-term subscription growth.

Together, these initiatives are intended to support a more scalable consumer business in which hardware facilitates customer acquisition and recurring digital services generate an increasing proportion of customer lifetime value.

Strategic Partnerships and Consumer Acquisition

The Company continued expanding its engagement with individuals and organisations operating across preventative health, cardiovascular health and longevity.

These relationships are intended to introduce CONNEQT's differentiated cardiovascular measurements to highly engaged consumer audiences while complementing traditional direct-to-consumer acquisition channels.



The signed partnership with Bryan Johnson and the Don't Die community influenced marketing expenditure during the September quarter, with the Company reducing selected paid acquisition activities in preparation for broader partnership-led initiatives.

The partnership has, however, taken longer to scale than originally anticipated, primarily due to the timing and scheduling of proposed marketing collaborations.

Management nevertheless believes that relationships with trusted preventative health communities are an increasingly important source of consumer awareness and customer acquisition, with the commercial scale and contribution of these partnerships expected to grow as the Company expands its market presence and distribution reach. Importantly, Pulse has now been adopted by two prominent figures in the global longevity community: Bryan Johnson, arguably the world's most well-known longevity influencer, and Kayla Barnes, the self-described "world's most tested woman." Their adoption provides valuable third-party validation of the technology and an opportunity to expand awareness and engagement among highly targeted health-conscious audiences.

In parallel, the Company is strengthening its owned marketing channels, including organic search, educational content, newsletters, email marketing and existing customer relationships.

These initiatives are intended to reduce dependence on paid advertising platforms and create more durable sources of consumer demand.

Digital (Care+ and In-App)

Building Recurring Revenue Beyond Hardware

Digital revenue recognised for the September quarter was \$0.05 million, an increase of 27% on the prior quarter (\$0.04 million). Digital revenue has increased in each quarter since in-app subscriptions were introduced in October 2025. Digital services represented approximately 11% of consumer revenue, compared with 3% in the prior quarter.

The increase in recognised revenue reflects the growing base of active Care+ subscribers. Though the percentage of new Pulse purchasers taking up Care+ plans increased (to 13%), the total number of new Care+ plans declined in the quarter due to lower device sales.

From August, Care+ subscriptions were also introduced within device bundles, with revenue from these bundled transactions reported within device and accessory sales. Early adoption of these bundles provides further evidence of consumer willingness to pay for integrated hardware and digital cardiovascular health services.



Strengthening the Care+ Proposition

The Company continues to develop Care+ as the recurring digital component of its consumer cardiovascular health platform.

The proposed evolution of Pulse pricing and feature availability is intended to establish a clearer distinction between essential blood pressure monitoring and premium cardiovascular health capabilities.

As described above, under the proposed model, our more advanced cardiovascular measurements and insights would be made available solely through Care+, creating a more direct relationship between the differentiated capabilities of the CONNEQT platform and recurring subscription revenue.

Management believes this approach has the potential to increase subscription attachment rates, strengthen customer engagement and improve lifetime customer value as more accessible device pricing drives broader adoption and expansion of the Pulse installed base.

The Company is also continuing to refine customer onboarding, lifecycle communications and digital subscription conversion opportunities.

New website experiences and dedicated landing pages are being developed to support more direct acquisition of CONNEQT app users and Care+ subscribers, creating additional entry points into the digital ecosystem beyond the initial hardware purchase.

Advancing the Digital Platform

CONNEQT continues progressing development of its next-generation digital infrastructure, including SphygmoCloud and its Software as a Medical Device programme.

The Company has received encouraging feedback through its FDA Pre-Submission engagement regarding its regulatory approach, with development and regulatory activities continuing.

Management is targeting March 2027 for the next major development milestone involving Pulse v2 (internally code-named “**CONNEQT Core**”) and its associated FDA-regulated Software as a Medical Device (SaMD) platform, subject to completion of development, validation and applicable regulatory requirements.

These initiatives are intended to establish a more scalable architecture for delivering advanced cardiovascular measurements and insights across CONNEQT's connected device ecosystem.



Over time, management believes this architecture will support the transition toward a software-enabled cardiovascular health platform, with recurring digital services becoming an increasingly important component of consumer revenue.

Reaffirming the Value of SphygmoCloud

Management believes it is important to reaffirm the significant strategic and commercial value of SphygmoCloud, which represents one of the Company's most important proprietary technology assets and a fundamental evolution of its business model.

Put simply, SphygmoCloud moves the processing of CONNEQT's proprietary cardiovascular biomarkers from individual devices into a centralised, cloud-based software platform.

Today, the CONNEQT Pulse performs its advanced cardiovascular measurements using proprietary technology embedded within the device itself. This requires specialised hardware components and associated processing capabilities, contributing to device manufacturing costs and limiting the Company's ability to scale its technology beyond its own hardware ecosystem.

SphygmoCloud fundamentally changes this architecture. By moving the processing and analysis of cardiovascular biomarkers into the cloud, the Company can make its advanced cardiovascular analytics accessible through compatible devices without requiring the same specialised processing capabilities to be embedded within the hardware.

The commercial rollout of SphygmoCloud is envisaged in two phases.

Phase 1 – CONNEQT Pulse v2: The first phase will see SphygmoCloud integrated with Pulse v2, which is intended to become the world's first SphygmoCloud-enabled device. This will enable the Company's proprietary cardiovascular biomarkers to be processed in the cloud and delivered through the CONNEQT app, significantly reducing device manufacturing and sales/customer acquisition costs while at the same time supporting a more affordable hardware offering and recurring subscription revenues.

Phase 2 – Third-party devices: The second phase is intended to extend SphygmoCloud's capabilities beyond CONNEQT's own hardware ecosystem, enabling compatible non-CONNEQT wellness devices to access the Company's proprietary cardiovascular biomarkers through the same cloud-based platform. This would create opportunities to license CONNEQT's technology to other device manufacturers and generate recurring software licensing and service revenues across the broader wellness and medical device industry.

This transition creates several significant commercial opportunities for the Company.



First, it enables a structurally lower-cost hardware model. By reducing the processing requirements within individual devices, CONNEQT can simplify its hardware architecture, materially reduce manufacturing costs and make devices more affordable to a broader consumer market. This supports the Company's strategy of maximising device adoption while monetising its proprietary biomarkers primarily through recurring software subscriptions.

Second, SphygmoCloud creates the opportunity to license CONNEQT's proprietary cardiovascular biomarkers to third-party device manufacturers. Rather than requiring partners to incorporate CONNEQT's specialised technology directly into their hardware, manufacturers of compatible conventional blood pressure monitoring devices could potentially access these advanced measurements through SphygmoCloud. This significantly expands the addressable market for the Company's technology beyond its own devices and creates opportunities for recurring software licensing and service revenues across the broader monitoring industry.

Third, the platform is designed to support a growing ecosystem of **SphygmoCloud-enabled devices**, allowing CONNEQT and potentially third-party manufacturers to develop new products that connect seamlessly to the same underlying cardiovascular analytics platform.

Importantly, the Company's FDA regulatory strategy is designed around clearance of SphygmoCloud as a Software as a Medical Device (SaMD) platform. As outlined through its FDA Pre-Submission engagement, CONNEQT will be seeking a regulatory framework under which subsequent compatible devices could utilise the cleared software platform with limited or potentially no additional FDA clearance requirements, subject to the characteristics of each device, its intended use and applicable regulatory requirements.

If successfully established, this should materially reduce the cost, complexity and time required to introduce new SphygmoCloud-enabled products, supporting a more rapid cadence of device development, licensing partnerships and commercial introduction.

The significance of SphygmoCloud therefore extends well beyond the launch of Pulse v2. It provides the potential for CONNEQT to evolve from a predominantly hardware-based cardiovascular technology business into a scalable software and analytics company, monetising its proprietary cardiovascular biomarkers across both its own growing installed base and a broader ecosystem of third-party devices.

Management believes this combination of proprietary cardiovascular analytics, a potentially reusable FDA-cleared software platform, device-agnostic licensing opportunities and recurring software revenues represents a highly differentiated capability.

As such, SphygmoCloud has the potential to create significant standalone strategic and commercial value for the Company, independent of the growth and economics of its own Pulse hardware business.



Priorities for the December Quarter

Management remains focused on advancing the transition toward a more scalable, software-led recurring revenue business, by driving Enterprise growth and restoring consumer growth, while improving customer acquisition efficiency and the lifetime economics of the consumer business.

Key priorities include:

1. **Drive Enterprise recurring revenue by adding new sites and increasing utilisation.**
2. **Restore website conversion performance** to pre-interruption levels before scaling paid acquisition expenditure, maintaining discipline around contribution margins and customer acquisition costs.
3. **Increase Care+ bundle adoption**, building on the 13% post-restock attachment rate and improving the contribution generated from each device transaction.
4. **Progress the new Pulse commercial pricing model**, with advanced cardiovascular features available through Care+, subject to validation of pricing, subscription adoption and customer economics.
5. **Expand organic and owned acquisition channels**, including existing customers, email, organic search, educational content and clinical partnerships.
6. **Advance strategic marketing partnerships**, progressing collaborations with Bryan Johnson, Kayla Barnes and other preventative health communities to expand consumer awareness and drive measurable customer acquisition.
7. **Progress Pulse v2 development and structural cost reductions**, including engineering, supply chain and product validation initiatives targeting more than 50% in device savings, ahead of its planned 2027 introduction through expanded direct-to-consumer (OTC) distribution channels.
8. **Advance SphygmoCloud development and FDA regulatory process**, progressing the Company's proposed SaMD platform towards FDA clearance, while establishing the foundation for future SphygmoCloud-enabled devices and potential third-party licensing opportunities.
9. **Strengthen recurring digital monetisation**, including Care+ subscription conversion, customer engagement and the development of additional premium cardiovascular health capabilities.

Management continues to work toward its internal FY27 revenue objectives while prioritising improved capital efficiency, sustainable customer acquisition and recurring digital revenue.

The Company believes the initiatives now underway will provide a stronger foundation for the next phase of Enterprise and Consumer growth and the transition to a scalable software and cardiovascular analytics business.



Corporate Update

Group revenue for the September quarter was \$1.18 million, up 86% on the September 2025 quarter and down 48% on the June 2026 quarter. Revenue by business (unaudited) is summarised below.

\$ million	Sep 2026 qtr	Jun 2026 qtr	Change	Sep 2025 qtr	Change
Consumer	0.45	1.39	(68%)	0.38	18%
Enterprise	0.03	0.04	(6%)	–	n/a
Research & pharma	0.70	0.85	(18%)	0.26	174%
Total revenue	1.18	2.28	(48%)	0.63	86%

Cash receipts from customers for the quarter were \$1.30 million, compared with \$1.88 million in the prior quarter. Receipts comprised approximately \$0.47 million (US\$0.33 million) from Pulse sales, compared with \$1.40 million (US\$1.0 million) in the prior quarter, and approximately \$0.83 million from research, pharmaceutical and enterprise customers, including collection of receivables outstanding at 30 June 2026.

Product manufacturing and operating costs were \$1.03 million, an increase of \$0.65 million on the preceding quarter, primarily reflecting payments to restock Pulse inventory following the supply interruption, together with deposits paid for future Pulse production. Inventory on hand increased by \$0.40 million during the quarter.

Advertising and marketing expenditure decreased by \$0.58 million (53%) to \$0.52 million, reflecting the reduction in paid customer acquisition during the period of constrained inventory.

Staff and employee benefits expenditure was \$2.00 million, a decrease of \$0.06 million on the preceding quarter. Administration and corporate costs decreased by \$0.19 million to \$0.46 million. Interest and other costs of finance paid of \$0.25 million relate to accrued interest on unsecured loans provided by C2 Ventures, a related party, which were converted to equity following shareholder approval (refer Capital Raising below).

Net cash used in operating activities was \$3.06 million, an increase of \$0.59 million on the preceding quarter, reflecting lower customer receipts, inventory restocking and the interest payment, partly offset by lower marketing and corporate costs.

Net cash from financing activities was \$1.00 million, comprising \$1.10 million of proceeds from the issue of shares, less capital raising costs of \$0.05 million and lease payments of \$0.06 million.

Closing cash at 30 September 2026 was \$0.50 million.



Payments to related parties and their associates during the quarter totalled \$0.34 million, comprising \$0.09 million of directors' fees and remuneration for services under existing service agreements and \$0.25 million of interest paid to C2 Ventures on unsecured loans that were converted to equity during the quarter.

Capital Raising

The Share Purchase Plan closed on 24 July 2026, with 17,227,296 shares issued on 7 August 2026 at \$0.022 per share, raising \$0.38 million.

Following shareholder approval at the Extraordinary General Meeting held on 15 September 2026, the Company issued Tranche 2 of the June 2026 Placement on 25 September 2026 at \$0.022 per share. This comprised:

- 68,181,818 shares (\$1.50 million) to C2 Ventures, satisfied by the conversion of \$1.275 million of unsecured loans advanced during FY2026 and \$0.225 million paid in cash that was immediately re-invested into shares during the quarter; and
- 20,934,707 shares (\$0.46 million) to other Placement participants.

A further 1,636,364 shares (\$0.04 million) were issued in satisfaction of amounts owing to directors, and 3,000,000 shares (\$0.07 million) were issued in lieu of cash for corporate advisory services.

Financing Facilities

The \$1.115 million R&D loan facility with Kashcade RD1 Pty Ltd remains fully drawn and matures on 30 November 2026. The facility is secured against the FY2026 R&D Tax Incentive refund of approximately \$1.5 million, which is expected to be received in the December 2026 quarter and will be applied to repay the facility. The balance will be used for working capital.

Funding

The Board is working on a funding package comprising both debt and equity that minimises shareholder dilution and enables the Company to continue to deliver on its plan, including:

- receipt of the FY2026 R&D Tax Incentive refund of approximately \$1.5 million, expected in the December 2026 quarter, which will be applied to repay the \$1.115 million Kashcade R&D loan facility;
- a new \$1.5 million R&D loan facility to be secured against the FY2027 R&D Tax Incentive refund, subject to due diligence and definitive documentation;



- an inventory funding facility of up to \$1.5 million to support CONNEQT Pulse inventory purchases, with a term sheet received subsequent to the quarter and progressing through due diligence and then documentation; and
- an equity capital raising, expected to be undertaken in the December 2026 quarter.

Further detail is provided in Item 8.6 of the accompanying Appendix 4C.

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations

Ben Henri

ben.henri@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com.au

About CONNEQT HEALTH

CONNEQT Health's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market-leading SphygmoCor® vascular biomarker technology. CONNEQT Health is listed on the Australian Stock Exchange ("ASX: CQT").